Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. - Abstract - Europe PMC
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer | Breast Cancer Research | Full Text
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspect
Fulvestrant in advanced breast cancer: evidence to date and place in therapy - Katalin Boér, 2017
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer | Journal of Medicinal Chemistry
Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review - Li - 2019 - Cancer Medicine - Wiley Online Library
Breast Cancer Update - Lynn Sage 2001
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives. - Document - Gale Academic OneFile
Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review - Li - 2019 - Cancer Medicine - Wiley Online Library
Estrogen alpha receptor antagonists for the treatment of breast cancer: a review | BMC Chemistry | Full Text
Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo
A Review of Fulvestrant in Breast Cancer | SpringerLink
IJMS | Free Full-Text | Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action | British Journal of Cancer
Mode of action of estradiol and fulvestrant. AF1: activation function... | Download Scientific Diagram
Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor α Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase | PLOS ONE
Breast Cancer Update - Lynn Sage 2001
FDA Expands Approval of Fulvestrant for Breast Cancer - NCI
Understanding the estrogen receptor signaling pathway: focus on current endocrine agents for breast cancer in postmenopausal wom
Ribociclib Improves Survival in Advanced Breast Cancer - NCI
Pure Antiestrogens - Selective Estrogen Receptor Modulators. Antonio Cano
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer | Future Oncology
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1) - Annals of Oncology
The molecular mechanism for the pure steroidal ERα antagonist,... | Download Scientific Diagram
Fulvestrant | SpringerLink
